SABBY MANAGEMENT LLC 13D and 13G filings for Virpax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-02 10:24 am Unchanged |
2023-12-31 | 13G | Virpax Pharmaceuticals, Inc. VRPX |
SABBY MANAGEMENT LLC | 0 0.000% |
0 (Unchanged) |
Filing |
| 2024-01-02 10:11 am Sale |
2023-12-31 | 13G | Virpax Pharmaceuticals, Inc. VRPX |
SABBY MANAGEMENT LLC | 0 0.000% |
-3,953 (Position Closed) |
Filing |
| 2023-01-10 1:36 pm Purchase |
2022-12-31 | 13G | Virpax Pharmaceuticals, Inc. VRPX |
SABBY MANAGEMENT LLC | 3,953 11.000% |
445 (+12.70%) |
Filing |
| 2022-01-04 11:31 am Sale |
2021-12-31 | 13G | Virpax Pharmaceuticals, Inc. VRPX |
SABBY MANAGEMENT LLC | 3,507 11.000% |
-493 (-12.32%) |
Filing |
| 2021-09-23 07:29 am Purchase |
2021-09-14 | 13G | Virpax Pharmaceuticals, Inc. VRPX |
SABBY MANAGEMENT LLC | 4,000 11.000% |
4,000 (New Position) |
Filing |